Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
Status:
Recruiting
Trial end date:
2026-07-26
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to characterize the long-term safety and efficacy of the
drug Deucravacitinib (BMS-986165) in patients who have been previously enrolled in an
applicable Phase 3 psoriasis study.